Month: May 2020

Waturu Holding A/S enters into letter of intent with Vejle Spildevand A/SThe importance for investors in Waturu Holding A/SA definitive agreement between Vejle Wastewater A/S and Waturu Holding A/S will result in Waturu Holding A/S, as described in our company description,initiating the sale of solutions to wastewater companies in Denmark and abroad.This would result in the requirement for investment in a larger dedicated organization as well as in production equipment.About Waturu Holding A/SWaturu Holding A/S is a Vejle based Greentech company, which develops innovative water technology for heating or treating water, with the focus on ensuring bacteria-free waterand reducing water and energy consumption for heating hot water in properties and thus ensuring CO2 savings.Waturu Holding A/S is a major shareholder in the medical company Watgen...

Waturu Holding A/S indgår hensigtserklæring med Vejle Spildevand A/SBetydningen for investorer i Waturu Holding A/SEn definitiv aftale mellem Vejle Spildevand A/S og Waturu Holding A/S, vil resultere i at Waturu Holding A/S, som beskrevet i vores virksomhedsbeskrivelse, vil igangsætte salg af løsninger til spildevandsselskaber i Danmark og i udlandet. Dette vil medføre et krav om investeringer i en større dedikeret organisation samt i produktionsudstyr.Hensigtserklæringens indholdSelskabet har indgået en hensigtserklæring med Vejle Spildevand A/S, om test af ny teknologi, som skal behandle overløbsvand samt forbedre slutbehandlingen af renset spildevand. Vejle Spildevand A/S, ejes 100% af Vejle kommune og renser årligt spildevand for 30.000 husstande og virksomheder. Waturu teknologien har flere fordele i forhold til behandling af urent...

Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020TEL AVIV, Israel, May 14, 2020 (GLOBE NEWSWIRE) — Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the positive results of a previously reported Phase 1 trial of CM-24, a monoclonal antibody targeting CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways, in patients with advanced cancer will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.  The presentation, titled, “Abstract 3094: A phase 1, open-label,...

– Company has sufficient capital to advance pipeline and fund operations through 2021 –BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced its financial results for the quarter ended March 31, 2020 and provided program updates.Recent HighlightsEntered into license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections (“COVID-19”).Entered into additional license agreement with KSURF to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds...

New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectivelyCompleted a $23 million underwritten public offering in February with an additional $5 million investment from Sol-Gel’s controlling shareholder in April, providing cash runway into mid-2021 and funds pre-commercialization efforts for Epsolay and TwyneoTop-line generic product revenue of $3.4 million in first quarter 2020NESS ZIONA, Israel, May 14, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the first quarter ended March 31, 2020 and provided an update on its clinical development programs.“In...

The Recylex Group (Euronext Paris: FR0000120388 – RX) indicates that today Weser-Metall GmbH, Harz-Metall GmbH, Norzinco GmbH and PPM Pure Metals GmbH have each applied for protective shield procedures 1 in accordance with Section 270 b (1) sentence 1 of German Insolvency law. Self-administration procedures 2 were applied for Recylex GmbH, C2P Germany GmbH and Recylex Grundstücksverwaltungsgesellschaft mbH. The objective which was to turnaround the Group as a whole, initiated during 2018, is now stopped due to the SARS-CoV-2 pandemic’s effects.The French companies of the Recylex Group are not in the scope of these German procedures. Recylex S.A. is assessing the consequences of this development on its activities.Sebastian Rudow, Chairman and Chief Executive Officer of Recylex S.A., commented:“The rapid developments caused...

Le groupe Recylex (Euronext Paris : FR0000120388 – RX) indique que, aujourd’hui, Weser-Metall GmbH, Harz-Metall GmbH, Norzinco GmbH et PPM Pure Metals GmbH ont chacune déposé une demande d’ouverture d’une procédure dite de « bouclier de protection »1 conformément à l’article 270 b (1) du Code allemand de l’insolvabilité (première phrase). L’ouverture d’une procédure dite de « gestion directe »2 a été sollicitée par Recylex GmbH, C2P Germany GmbH et Recylex Grundstücksverwaltungsgesellschaft mbH. L’objectif qui était de redresser le Groupe dans son ensemble, initié en 2018, est ainsi interrompu en raison des effets de la pandémie de SARS-CoV-2.Les sociétés françaises du Groupe Recylex ne sont pas dans le périmètre de ces procédures de droit allemand. Recylex S.A. étudie les conséquences de cette situation sur ses activités.Sebastian...

Phase 1/2 Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Ongoing; Study Startup ActivitiesProgressing for Phase 1/2 Trials of PR001 for Type 2 Neuronopathic Gaucher Disease and PR006 forFrontotemporal Dementia with GRN MutationsData Presentations Highlight Potential of AAV Gene Therapy Approach toSlow or Stop Neurodegenerative Disease Progression in Preclinical ModelsNEW YORK, May 14, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today reviewed recent business highlights and reported financial results for the first quarter ended March 31, 2020.“We are excited to continue the clinical development of PR001 and are on track to report interim data for a subset of patients...

TEL AVIV, Israel, May 14, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2020, and provided a corporate update.“We reached an important milestone in our development of VB-111 in ovarian cancer with the recent positive outcome of the interim analysis of the ongoing Phase 3 OVAL study, which demonstrated the potential benefit of VB-111 over standard-of-care in a randomized-controlled study,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “A second planned interim analysis which will assess overall survival in the two treatment arms, is expected in the third quarter this year. We are pleased to be making progress also in our MOSPD2 antibody programs. We recently presented promising new data in NASH and colitis models in a Poster of...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, May 14, 2020 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX-V: EMO) (the “Company” or “Emerita”) intends to complete a non-brokered private placement financing of up to 20,000,000 units of Emerita (the “Units”) at a price of $0.05 per Unit for gross proceeds of up to $1,000,000 (the “Offering”).  Each Unit shall be comprised of one common share of Emerita (each a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant shall entitle the holder to acquire one Common Share at a price of $0.15 for a period of 24 months following the closing date of the Offering, subject to an acceleration provision whereby in the event that at any time after the expiry of the statutory hold...